Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds
- Resource Type
- Article
- Source
- In
Clinical Therapeutics October 2017 39(10):2024-2037 - Subject
- Language
- ISSN
- 0149-2918